Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00103831 | Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer | PHASE1 | COMPLETED | - | — | — | - | - | Mar 2, 2010 | 3 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| Oral Taxane | DRUG | - |
Inclusion Criteria: * Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions. * ECOG Performance Status 0-2 Exclusion Criteria: * Inability to swallow capsules * Recent significant cardiovascular disease * Women who are pregnant or breastf...